Poly(ADP-ribose) polymerase (PARP) enzymes (numbering seventeen in total) have drawn considerable attention as drug targets in the last decade owing to the clinical success of non-selective PARP1/2 inhibitors Olaparib, Talazoparib, Niraparib and Rucaparib approved for cancer treatment.1 Here, PARP1 is linked to cancer.